Resources

Resources

  • Publication

    Developing A Monitoring And Evaluation Framework For Viral Load Testing

    The 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommend viral load as the preferred monitoring approach to diagnose and confirm ART failure. As countries invest in the scale-up of routine viral load testing, it is critical to measure the impact and progress towards achieving the UNAIDS target of 90% viral suppression amongst patients on ART by 2020. This document presents key considerations and examples of tools (provided in the appendices) to assist countries in developing a national viral load (VL) monitoring and evaluation (M&E) plan.

     Author(s) WHO   Originally published on October 1, 2018   Posted on November 15, 2018


  • Publication

    What’s New In Treatment Monitoring: Viral Load And CD4 Testing

    Treatment initiation

    • ART should be initiated in all children, adolescents, pregnant and breastfeeding women and adults living with HIV, regardless of WHO clinical stage and at any CD4 cell count.
    • ART should be initiated in all children, adolescents, pregnant and breastfeeding
      women and adults living with HIV, regardless of WHO clinical stage and at any CD4 cell count.
    • As a priority, ART should be initiated in all children, adolescents and adults with severe or advanced HIV clinical disease and adults with a CD4 count ≤ 350 cells/mm3 as well as children < 5 years of age with WHO clinical stage 3 or 4 or CD4 count ≤ 750 cells/mm3.

     Author(s) WHO   Originally published on July 1, 2017   Posted on November 15, 2018


  • Publication

    Technical And Operational Considerations For Implementing HIV Viral Load Testing

    This publication provides high-level guidance on implementing and scaling up HIV viral load testing programmes for health ministries and implementation partners, using a three-phased approach: (1) planning; (2) scale-up; and (3) sustainability. The guidelines for managing antiretroviral therapy (ART) issued by WHO have recognized the importance of viral load monitoring since 2003. Routine viral load monitoring is now strongly
    recommended as the monitoring strategy of choice.

     Author(s) WHO   Originally published on July 1, 2014   Posted on November 15, 2018


  • Publication

    Considerations For Adoption And Use Of Multi-disease Testing Devices In Integrated Laboratory Networks

    Several new laboratory technologies are available or are being developed to allow for testing of different conditions using disease-specific tests on the same platform. For example, a single device may be able to test for the presence of tuberculosis (TB) and HIV, and quantitatively measure HIV and hepatitis C viral load by using disease-specific reagents or cartridges with self-contained nucleic acid testing technology. Some of these technologies are being designed for use at centralized reference laboratories while others
    may be positioned for use at or near to point of care.

     Author(s) WHO   Originally published on June 1, 2017   Posted on November 15, 2018


Filter by ticking the boxes below and then click apply


projects

  • SLIPTA
  • APHLN
  • LabCop
  • Point-of-Care
  • Laboratory Mapping
  • Other

resource type

  • Publication
  • Report
  • Guidelines
  • White paper
  • Blog article
  • Other

health topics

  • HIV/AIDS
  • HIV Co-infections
  • Maternal & Child Health
  • Other Health Topics
  • Hepatitis B
  • Hepatitis C
  • Syphilis
  • Tuberculosis
  • Ebola
  • Antimicrobial Resistance

development and evaluation

  • Diagnostic Landscapes
  • Systematic Reviews
  • Target Product Profiles
  • Protocols
  • Evaluation sites
  • Evaluation methods
  • Test performance
  • Other

policy and implementation

  • Models
  • Technology Assessment
  • Toolkits
  • Quality Assurance
  • Point of Care Testing (POCT)
  • Other
  • General

regulation

  • Regulating IVDDs
  • National/Regional Overviews
  • Harmonization Initiatives
  • Other Regulatory Topics